Biosimilars in an era of rising oncology treatment options.

Peeters, Marc; Planchard, David; Pegram, Mark; Gonçalves, João; Bocquet, François; Jang, Harah

Peeters, Marc; Planchard, David; Pegram, Mark; Gonçalves, João; Bocquet, François; Jang, Harah.

Afiliação

Peeters M; Department of Oncology, Antwerp University Hospital, Belgium.
Planchard D; Department of Medical Oncology, Thoracic Unit, Institut Gustave Roussy, Villejuif, France.
Pegram M; Stanford Comprehensive Cancer Institute, Stanford University School of Medicine Stanford, CA, USA.
Gonçalves J; iMed-Research Institute for Medicines, Faculty of Pharmacy at University of Lisbon, Lisbon, Portugal.
Bocquet F; Oncology Data Factory & Analytics Department, Institut de Cancérologie de l'Ouest, Nantes-Angers, France.
Jang H; Samsung Bioepis Co., Ltd, Incheon, Republic of Korea.

Future Oncol ; 17(29): 3881-3892, 2021 Oct.

Article em En | MEDLINE | ID: mdl-34189937

Assuntos

Medicamentos Biossimilares/uso terapêutico; Oncologia/métodos; Neoplasias/tratamento farmacológico; Humanos

Palavras-chave

biologics; biosimilars; breast cancer; colorectal cancer; lung cancer; molecular profiling; monoclonal antibodies; oncology treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicamentos Biossimilares / Oncologia / Neoplasias Limite: Humans Idioma: En Revista: Future Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google